Rotavirus vaccine could save millions of lives: study
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A vaccination campaign to combat rotavirus in the world's poorest countries could save the lives of hundreds of thousands of children, according to a pair of studies published this week.
Around the world, more than half a million infants and children die each year from rotavirus infection, a leading cause of severe diarrhea in children under the age of five, with more than half of the reported cases in sub-Saharan Africa.
The studies published in this week's New England Journal of Medicine found that vaccination campaigns in Malawi and South Africa reduced the rate of rotavirus infections by 61.2 percent during the first year of life, while another campaign in Mexico saw diarrheal disease rates drop by over 65 percent.
In industrialized countries, the vaccine is part of a standard pediatric immunization protocol.
"We now have another powerful weapon to add to our armamentarium to combat diarrheal deaths - rotavirus vaccines," John Hopkins University health professor Mathuram Santosham wrote in an editorial accompanying the studies' results.
"Rotavirus vaccine should be introduced immediately in high mortality areas and it should be used as a trigger to energize diarrhea control programs and improve coverage for all the proven interventions for diarrhea."
More than 4,900 infants were enrolled in the Phase III clinical trial in Malawi and South Africa testing the Rotarix rotavirus vaccine, which is developed by British pharmaceutical group GlaxoSmithKline Biologicals.
GlaxoSmithKline and a collaborative partnership involving the non-governmental group PATH, the World Health Organization and the US Centers for Disease Control and Prevention co-funded the study.
The Mexico study looked at the impact of vaccination on diarrheal deaths in Mexican children between 2008 and 2009 after a phased introduction of the orally administered Rotarix vaccine.
"The efficacy of the vaccine coupled with the high rates of rotavirus incidence and severity in low-resource countries point to the dramatic potential rotavirus vaccines hold toward reducing child mortality among the world's most vulnerable populations," said African clinical trial study author Shabir Madhi.
"The vaccine can make a significant impact in global public health if investments are made to bring them to all children, particularly those in the world's poorest countries," added Madhi, co-director of the South African Medical Research Council at the University of Witwatersrand in Johannesburg.
js/oh/sg
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments